SPG21

SPG21 (maspardin/ACP33) is a cytosolic protein that governs late endosomal/lysosomal homeostasis by acting as a RAB7A effector, and its loss causes the autosomal recessive neurodegenerative disorder Mast syndrome (SPG21) (PMID:14564668, PMID:40833810). Maspardin localizes to endolysosomal membranes through direct binding to GTP-bound RAB7A, a step disrupted by disease-associated variants that reduce SPG21 expression (PMID:40833810, PMID:41400694). At this compartment maspardin selectively restrains the noncanonical mTORC1 substrate TFEB—without affecting canonical substrates ULK1, S6K1, or 4E-BP1—so that SPG21 loss reduces TFEB phosphorylation and drives TFEB nuclear translocation and upregulation of TFEB target genes (PMID:40833810, PMID:41400694). Mechanistically, maspardin loss redistributes RAB7 from retromer-positive late endosomes to lysosomes, weakening RAB7's interaction with the GAP TBC1D5 so that RAB7 remains GTP-loaded, recruiting FYCO1 and promoting anterograde lysosome motility along microtubules (PMID:41400694). The alpha/beta hydrolase fold domain mediates peptide binding rather than catalysis, as first defined through its interaction with the cytoplasmic tail of CD4 (PMID:11113139). In neurons, maspardin is required for normal EGF-EGFR signaling and limits axon branching, and its loss produces excessive axonal branching, impaired neuronal maturation, and progressive motor dysfunction in knockout mice (PMID:20661613, PMID:26978163).

1. 2000 Medium

   Established maspardin as a peptide-binding protein, showing its alpha/beta hydrolase fold acts as a protein-interaction module rather than a catalytic enzyme by binding the cytoplasmic tail of CD4 and dampening T-cell activation.

   Evidence Yeast two-hybrid screen, co-immunoprecipitation, and deletion mutagenesis mapping

   PMID:11113139

   Open questions at the time

   • Relevance of CD4 binding to neuronal/endolysosomal function not connected
   • No catalytic activity demonstrated or excluded for the hydrolase fold
2. 2003 Medium

   Defined SPG21 as a disease gene by linking a loss-of-function frameshift mutation to Mast syndrome, establishing that maspardin deficiency causes neurodegeneration.

   Evidence Homozygosity mapping and patient DNA sequencing identifying 601insA frameshift in all affected cases

   PMID:14564668

   Open questions at the time

   • Localization inferred from prior work, not directly demonstrated
   • Molecular consequence of mutation on protein function untested at this stage
3. 2009 Medium

   Provided the first protein-interaction map beyond CD4 and refined subcellular localization to trans-Golgi/late endosomal compartments, identifying ALDH16A1 as a maspardin partner.

   Evidence IP-mass spectrometry, co-IP of overexpressed proteins, fusion protein pull-down, and colocalization imaging

   PMID:19184135

   Open questions at the time

   • Functional significance of the ALDH16A1 interaction unresolved
   • Interaction validated only with overexpressed proteins in a single lab
4. 2010 Medium

   Connected maspardin loss to a defined neuronal phenotype, showing knockout mice recapitulate progressive motor dysfunction and that maspardin restrains axon branching.

   Evidence Homologous recombination knockout mouse with behavioral testing and primary cortical neuron morphology

   PMID:20661613

   Open questions at the time

   • Molecular pathway linking maspardin to axon branching unidentified
   • Cell-autonomy of the motor phenotype not dissected
5. 2016 Medium

   Placed maspardin within a growth-factor signaling axis, showing it is required for EGF-induced neuronal growth and EGF-EGFR target gene expression.

   Evidence SPG21-/- primary cortical neuron culture, behavioral tests, and quantitative RT-PCR of EGF signaling targets

   PMID:26978163

   Open questions at the time

   • Direct biochemical link between maspardin and EGFR signaling not established
   • How attenuated EGF signaling relates to endolysosomal function unknown
6. 2025 High

   Resolved the core molecular mechanism: maspardin is a RAB7A effector that controls RAB7 nucleotide state and lysosome positioning, selectively gating noncanonical mTORC1 phosphorylation of TFEB.

   Evidence Two independent studies using SPG21 knockout/knockdown cells with GTP-specific RAB7 co-IP, TBC1D5/FYCO1 interaction assays, TFEB phosphorylation and nuclear translocation imaging, and lysosome motility assays

   PMID:40833810 PMID:41400694

   Open questions at the time

   • Direct mechanism by which maspardin promotes TFEB phosphorylation at the lysosome not fully defined
   • How disease variants mechanistically impair RAB7 binding beyond reduced expression unresolved
   • Whether the neuronal axon-branching/EGF phenotypes derive from the RAB7-TFEB axis untested

• It remains unknown how the endolysosomal RAB7-TFEB regulatory role of maspardin mechanistically produces the neuronal axon-branching, EGF-signaling, and progressive motor phenotypes of Mast syndrome.
• No in vivo demonstration that TFEB dysregulation drives the SPG21 motor phenotype
• Catalytic versus scaffolding role of the hydrolase fold in RAB7 effector function unresolved